Description: IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in the United States and the Netherlands. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand; and COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. In addition, it engages in laboratory analysis. The company was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.
Home Page: www.igeapharma.nl
Siriusdreef 17
Hoofddorp,
2132 WT
Netherlands
Phone:
31 23 568 9494
Officers
| Name | Title |
|---|---|
| Mr. Vinvcenzo Moccia | CEO, Exec. Director & Interim CFO |
| Ms. Rosanna Squitti | Research Director and Head of R&D |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0463 |
| Price-to-Sales TTM: | 106.8248 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |